Thymosin Alpha-1
Thymic peptide studied as an immune modulator across infection and critical-illness settings.
Mixed human evidenceExplore this ingredient →← All stacks & combinationsINGREDIENT INGREDIENT POPULAR GOALS THE COMMUNITY RATIONALE THE OPEN QUESTION THYMOSIN ALPHA-1 LL-37 Human study · LL-37 wound care Regulatory guidance · ingredient safety
Community combination
Thymosin Alpha-1 + LL-37
The body’s defences provide the common ground for Thymosin Alpha-1 + LL-37. Each ingredient has immune-related research, but the combination remains uncertain.
Immune & Inflammation
01
THE BUILDING BLOCKS
What’s in it?
LL-37
Human cathelicidin peptide studied in host defence, inflammation and wound healing.
Early topical human evidenceExplore this ingredient →The ingredients listed here do not specify a particular product or mixing ratio. Pre-mixed products may differ from the formulations used in research.
02
PEOPLE & EXPERIENCE
Why this combination is discussed
The body’s defences provide the common ground for Thymosin Alpha-1 + LL-37. Each ingredient has immune-related research, but the combination remains uncertain.
Immune & Inflammation
Interest in this pairing comes from research into immune responses and the body’s defences.
LL-37 has been studied as a treatment applied to wounds. That research does not establish how this combination affects the immune system or whether it treats infections.
Community experience can explain why a pairing has become popular. It cannot show whether the ingredients work better together or whether a mixed product is stable, accurately dosed or safe.
03
THE REASON FOR INTEREST
Why people combine them
Interest in this pairing comes from research into immune responses and the body’s defences.
How their research overlaps
LL-37 has been studied as a treatment applied to wounds. That research does not establish how this combination affects the immune system or whether it treats infections.
The individual profiles explain each ingredient’s potential benefits and research. Even when their effects seem complementary, studies are needed to find out whether using them together adds a benefit.
04
No human combination study found in this searchWHAT THE RESEARCH CAN SUPPORT
Evidence for this combination
We did not find a human study testing these ingredients together in our targeted search. That leaves their combined benefits and safety uncertain; it does not show that the pairing is ineffective.
The LL-37 study looked at treatment applied to wounds. It does not establish the effects of injecting LL-37 with thymosin-alpha-1.
Explore the sources below ↓05
RESEARCH & COMMUNITY CONTEXT
Doses & duration
Start with each ingredient—not an invented combined dose
No validated combined starting dose exists. The cards below preserve the practical structure people look for while keeping each ingredient’s reported pattern separate.
Anecdotal / unvalidated · borrows a clinical amount
- Starting point discussed
- A recurring community pattern borrows the older 1.6 mg clinical amount and uses it twice weekly rather than the intensive-care schedules.
- Duration / cycle
- Four-to-eight-week cycles are commonly discussed for broad immune-resilience goals, but this duration has not been validated in a general wellness trial.
- Continuation / break
- People discuss a pause and reassessment after a cycle; no evidence-based maintenance or break interval has been established.
Anecdotal / unvalidated · not equivalent to topical trials
- Starting point discussed
- Community injection descriptions often start around 100 mcg/day and may move toward 200 mcg/day. These amounts have no validating human dose-finding study.
- Duration / cycle
- Short 2–4-week courses are commonly described; topical use is product- and wound-specific.
- Continuation / break
- No validated systemic titration, maintenance or break schedule exists.
Using two ingredients in the same period and mixing them in one vial or syringe are different questions. Separate schedules cannot establish compatibility, interactions or a safe combined total.
06
WHAT REMAINS UNCERTAIN
Safety & uncertainties
- The combination needs its own safety research, including possible interactions and side effects.
- What a product contains, how it is made and how it is used all matter. Products sold under the same name may differ.
- A clinician can assess how existing medicines or health conditions affect the risks. These pages provide general information, not personal treatment advice.
07
FOLLOW THE EVIDENCE
Sources & search record
Last source check: 14 September 2026
Each link explains what it covers: the combination itself, an individual ingredient or safety information. A trial record and a paper can describe the same study.
Grönberg et al., 2014 — topical LL-37 venous-ulcer trial ↗
A study of LL-37 applied to wounds. Thymosin-alpha-1 was not part of the treatment.
FDA: peptide compounding safety concerns ↗
Safety information about individual ingredients, rather than the combination. This is US guidance, not a statement of UK legal status.
About this search
We used targeted web searches for ingredient pairs, including searches focused on PubMed and ClinicalTrials.gov. We followed relevant papers, research reviews and FDA safety information, checking whether the ingredients were actually given together and how they were used. Some full papers were unavailable, so we relied on their published summaries. Web searches can miss studies: this was a targeted source check, not an exhaustive or systematic review, a clinical assessment or a review of UK regulation. The links below let you explore further; search results are not evidence on their own.
Search terms used
- "thymosin alpha 1" "LL-37" combination trial
- "thymosin alpha-1" "LL-37" site:pubmed.ncbi.nlm.nih.gov
- "thymalfasin" "LL-37" site:clinicaltrials.gov
Search for these ingredients together:
Studies may use different names for the same ingredient. The search terms above show which alternatives we checked. Community experiences can explain interest in a stack, but we did not count anecdotes or seller claims as clinical studies.